Abstract
Meeting abstracts Immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies has demonstrated overall survival benefits in patients (pts) with metastatic melanoma (MM) compared to previous standard therapy. Two randomised clinical trials indicate that combined anti-CTLA-4 and anti-PD-1 antibody
Highlights
Immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies has demonstrated overall survival benefits in patients with metastatic melanoma (MM) compared to previous standard therapy
We retrospectively identified pts with MM who received anti-PD-1 therapy (Nivolumab/Pembrolizumab) and were subsequently treated with ipilimumab
Ipilimumab was administered at a dose of 3mg/kg every three weeks for four doses and response assessed by CT scan 4-6 weeks after the last dose
Summary
Immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies has demonstrated overall survival benefits in patients (pts) with metastatic melanoma (MM) compared to previous standard therapy. Methods We retrospectively identified pts with MM who received anti-PD-1 therapy (Nivolumab/Pembrolizumab) and were subsequently treated with ipilimumab. Ipilimumab was administered at a dose of 3mg/kg every three weeks for (up to) four doses and response assessed by CT scan 4-6 weeks after the last dose.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call